CHRISTINA SLOAN: Open Payments
NPI 1831151273 · CHANDLER, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,022 in 54 payments from 19 companies in 2025. Trend: 2023 $1,276 · 2024 $1,042 · 2025 $1,022
Food & beverage: $1,022
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 17 | $266 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $107 |
| Ardelyx, Inc. | 3 | $80 |
| Ipsen Biopharmaceuticals, Inc | 3 | $71 |
| Aimmune Therapeutics, Inc. | 3 | $51 |
| Janssen Biotech, Inc. | 2 | $48 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $48 |
| GENZYME CORPORATION | 2 | $47 |
| QOL Medical, LLC | 2 | $43 |
| Novo Nordisk Inc | 2 | $43 |
Products named: RINVOQ, ENTYVIO, SKYRIZI, IBSRELA, IQIRVO, DUPIXENT, ZENPEP, LINZESS.
Industry payments across AZ — which companies pay providers there.
